Brimonidine topical gel

Drug Profile

Brimonidine topical gel

Alternative Names: Brimonidine tartrate gel; CD 07805/47; COL 118; Col-118; Mirvaso; Onreltea; Sansrosa; SR-101

Latest Information Update: 14 Jul 2016

Price : $50

At a glance

  • Originator SansRosa Pharmaceutical Development
  • Developer Galderma
  • Class Antiglaucomas; Antihypertensives; Quinoxalines
  • Mechanism of Action Alpha 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Erythema

Most Recent Events

  • 12 Oct 2015 No recent reports on development identified - Phase-II for Erythema in USA (Topical, twice-daily dosing)
  • 30 Jun 2014 Galderma completes a phase II trial in Erythema (prevention) in Germany (EudraCT2013-005083-26)
  • 28 Feb 2014 Phase-II clinical trials in Erythema (prevention) in Germany (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top